is chronic allergic conjunctivitis that is most regularly seen in young males. Though most kinds of allergic conjunctivitis do not disturb vision, VKC is rare in that harms the cornea from the situation results in vision loss. Although it is usually seasonal, year-round symptoms can be seen, which can lead to indeterminate diagnoses being made.
High prevalence of vernal keratoconjunctivitis is projected to propel growth of the global vernal keratoconjunctivitis market over the forecasted period. For instance, as per the study, ‘Prevalence of vernal keratoconjunctivitis and its related factors between children in Gambella town, southwest Ethiopia, June 2018’, issued in PLoS One, the incidence of vernal keratoconjunctivitis was 11.10%. The mounting population and growing prevalence of VKC creates large patient inhabitants in the market. For instance, in 2017, overall 4,752,356 patients were affected by VKC in the global market. Moreover, China adds the largest share among EU-5, and Japan, with 2,248,706 cases in 2017. The total detected prevalent population of VKC was around 2,943,057 in the world.
Click Here to Access the Free Sample Report @ https://analyticsmarketresearch.com/sample-request/vernal-keratoconjunctivitis-market/57615/
The global demand for vernal keratoconjunctivitis market was predicted to be about USD 450 million in 2022, and by the end of 2031, existing and expected developments would hit valuations of around USD 730 million. The industry players and analysts predict the global Vernal keratoconjunctivitis market growth of around 6.5% in terms of CAGR. During the forthcoming years, growth in the incidence of ophthalmic disorders, increasing government initiatives, development in treatment options, rising focus of pharmaceutical companies on the growth of enhanced and new medicine for the management of vernal keratoconjunctivitis, and growing awareness are the factors that will increase the global vernal keratoconjunctivitis market. However, high cost of treatment, stringent regulatory situations, side-effects of few eye allergic treatments, and indeterminate reimbursement scenario will act as restrictions for the growth of this market.
Some of the leading and top vernal keratoconjunctivitis companies in the global vernal keratoconjunctivitis market include Akari Therapeutics, Allakos Inc., iCo Therapeutics, Novartis Pharmaceuticals, Santen, Senju Pharmaceutical, Alcon Vision LLC among others. The leading five players such as Akari Therapeutics, Allakos Inc., iCo Therapeutics, Novartis Pharmaceuticals, Santen, Senju Pharmaceutical hold around 40% market share of the global vernal keratoconjunctivitis market.
On the basis of drug type, the global vernal keratoconjunctivitis market can be segmented into Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, and others with the ‘Bertilimumab’ category having the leading market share of about 29 percent, closely followed by the “Verkazia” category at about 20 percent of the global vernal keratoconjunctivitis market share. Based on treatment type, the vernal keratoconjunctivitis market is segmented into tablets, ointments, gels, and others. On the basis of distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In terms of geography, North America region held the leading market share of around 40% among other regions such as Asia Pacific, Europe, Latin America, and Middle East & Africa in the global Vernal keratoconjunctivitis market.
Analytics Market Research
99 WALL STREET, #2124 NEW YORK, NY 10005